03.14.25 -- EMA On Qualifying Non-Mutagenic Impurities For Drug Toxicological Safety

Explore how shifting demand for oligos and peptides is driving outsourcing relationships and innovation in CDMO partnerships. Join our next Outsourced Pharma Live as we cover best practices for outsourcing these specialized therapeutics, focusing on capacity, regulatory challenges, and technology transfer. Register today to learn about the unique challenges and opportunities in scaling production for these complex molecules.

Technology transfer is a crucial process in the pharmaceutical industry, ensuring drugs developed in labs can be manufactured consistently at scale.

Learn more about spray drying, and explore case studies detailing its success as a critical tool in developing innovative and effective lung cancer therapies.

In this session, Chief Scientific Officer Dr. Andy Lewis delves into the key drivers shaping peptide drug development and explores innovative delivery options to enhance therapeutic outcomes.

A pharmaceutical company facing storage space issues decided to outsource its reference samples to Q1 Scientific, a stability storage service provider, resulting in cost savings.

Dr. Bert Metten, Tech. Dev. Manager at Ajinomoto Bio-Pharma Services, explores dangerous chemistries and continuous flow processes for the manufacture of safe, efficacious, cost-effective products.

Artificial intelligence (AI) has made its way to the midsection of our new-drug life cycle, now enabling route-scouting and data scientists at drug sponsors and at your CDMOs. What does this look like in practice? Will there be fewer process chemists in the future, and who will they be?

Our innovative business model won't add additional costs to your project. Check out our network's process development and preclinical manufacturing capabilities to simplify your outsourcing solutions.

Review our expertise across a wide range of global markets. Our experience in securing regulatory approvals and navigating market challenges positions us as a trusted partner.

If the material is not adequately blinded, clinical trial participants may be able to tell the difference between the real drug and the placebo, resulting in a biased trial and a loss on your investment.